Truvada 200 mg/245 mg film-coated tablets
Sponsors
Fundacion Seimc Gesida, Fundacion Seimc Gesida, Inserm, Stichting Radboud universitair medisch centrum, Fondazione Penta Ets
Conditions
HIV preventionHIV-1 infectionHIV-infectedMetabolic liver disease in HIV-infected people
Phase 3
ANRS0392s ELDORADO : Phase III, open-label, randomized, multicenter trial EvaLuating the non-inferiority of DORAvirine versus DOlutegravir based antiretroviral regimens in treatment-naïve people living with HIV-1 infection
RecruitingCTIS2023-508626-10-00
Start: 2025-01-08Target: 60Updated: 2025-10-15
Impact of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis persistence and coverage in men who have sex with men in France: a randomized controlled clinical trial.
RecruitingCTIS2024-510678-25-00
Start: 2025-05-14Target: 322Updated: 2025-11-14
A randomised non-inferiority trial with nested PK to assess DTG/3TC fixed dose formulations for the maintenance of virological suppression in children with HIV infection aged 2 to <15 years old
Active, not recruitingCTIS2024-520388-15-00
Start: 2023-06-30Target: 6Updated: 2025-08-12
Phase 4
Phase IV comparative, randomized, open-label pilot study to evaluate the efficacy and safety of a rilpivirine-based antiretroviral treatment regimen in HIV-infected patients with metabolic liver disease who maintain undetectable HIV viral load
CompletedCTIS2022-503110-23-00
Start: 2023-05-05End: 2025-07-07Target: 75Updated: 2023-08-28
Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA)
CompletedCTIS2024-515487-31-00
End: 2025-12-12Target: 163Updated: 2024-10-22